You are on page 1of 30

See

discussions, stats, and author profiles for this publication at: http://www.researchgate.net/publication/215566514

FORMULATION AND EVALUATION OF


EFFERVESCENT TABLETS OF PARACETAMOL
ARTICLE JANUARY 2011

CITATIONS

DOWNLOADS

VIEWS

31,044

2,708

8 AUTHORS, INCLUDING:
Palanisamy P
Vinayaka Missions University
10 PUBLICATIONS 9 CITATIONS
SEE PROFILE

Available from: Srinath Kashi


Retrieved on: 23 July 2015

Srinath et al., IJPRD, 2011; Vol 3(3): 12; May 2011 (76 - 104)

International Standard Serial Number 0974 9446

[Research Article]

-------------------------------------------------------------------------------------------------------------------------------------------------FORMULATION AND EVALUATION OF EFFERVESCENT TABLETS OF PARACETAMOL


K.R.Srinath*1, C. Pooja Chowdary1,
Palanisamy.P2, Vamsy Krishna.A2,
S. Aparna1, Syed Shad Ali1, P. Rakesh1, K.Swetha3
1

Pulla Reddy Institute Of Pharmacy, Dundigal, Medak, Andha Pradesh, India


Vinayaka Missions College Of PharmacyVinayakamission University,Salem, TN
3
Cm College Of Pharmacy, Maisammaguda, Dulapalli, Secunderabad, Andha Pradesh
2

ABSTRACT
The oral dosage forms are the most popular way of taking medication despite
having some disadvantages like slow absorption and thus onset of action is
prolong. This can be overcome by administrating the drug in liquid from but,
many APIs have limited level of stability in liquid form. So, Effervescent Tablets
acts as an alternative dosage form. The tablet is added into a glass of water just
before administration and the drug solution or dispersion is to be drunk
immediately. The tablet is quickly broken apart by internal liberation of CO2 in
water due to interaction between tartaric acid and citric acid with alkali metal
carbonates or bicarbonates in presence of water. Due to liberation in CO2 gas,
the dissolution of API in water as well as taste masking effect is enhanced. The
advantages of effervescent tablets compared with other oral dosage forms
includes an opportunity for formulator to improve taste, a more gentle action on
patients stomach and marketing aspects. In present work an attempt has been
made to formulate an effervescent tablet containing immediate release of
paracetamol using various acids and bases. In present work we are used
different acids and bases in different concentration. In the preformulation study,
compatibility evaluation was performed which implies that drug; acids, bases
and other excipient are compatible with each other. The formulation of tablets
was done by using wet granulation as well as dry granulation in that technique
wet granulation which was found acceptable.The total nine placebo tablets were
prepared and evaluated for hardness, disintegration time, weight variation and
solubility. All the formulation shows hardness and weight variation with in limit
but the combination of citric acid (12.56%), tartaric acid (25.17%), sodium
bicarbonate (38.20%), sodium carbonate (6.41%) ,binding agent PVP-K-30
(2.94%) and sodium benzoate (0.52%). for the final formulation,(F7) Because
these ingredients shows the good effervescent reaction and has no problem in
capping and sticking like other formulation

Correspondence to Author

Mr. K.R.Srinath
Pulla Reddy Institute Of
Pharmacy, Dundigal, Medak,
Andha Pradesh, India

Email
palanisamy2907@gmail.com
Key Words
Mucoadhesion, bioadhesion,
oral mucosa, mucin.

INTRODUCTION

Available online on www.ijprd.com


Its free to download

76

International Journal of Pharmaceutical Research & Development

Effervescent tablet:
The oral dosage forms are the most popular way of
taking
medication
despite
having
some
disadvantages like slow absorption and thus onset of
action is prolong. This can be overcome by
administrating the drug in liquid from but, many APIs
have limited level of stability in liquid form. So,
effervescent tablets acts as an alternative dosage
form. The tablet is added into a glass of water just
before administration and the drug solution or
dispersion is to be drunk immediately. The tablet is
quickly broken apart by internal liberation of CO2 in
water due to interaction between tartaric acid and
citric acid with alkali metal carbonates or
bicarbonates in presence of water.

ISSN: 0974 9446

opening the container can also result in loss of product


quality. The most commonly used effervescent tablet
today is aspirin tablet.
The aim of this study is to develop and physicochemically evaluate the Effervescent Tablets of
Paracetamol. To enhance the onset of action of
Paracetamol and increase the solubility of Paracetamol.
 To produce faster onset of action
 To achieve better patient compliance.
 To Avoid the First Pass Effect.
The Effervescent tablets should have satisfactory
property.
Tablet having the greater bioavailability than other
dosage form.
The stability of Effervescent tablets can be increased.
The effervescent tablets require strictly humid
control area. The Effervescent
tablets can be made in a normal area where the
humidity and temperature Condition not
maintained.

Effervescent Tablets
Due to liberation in CO2 gas, the dissolution of API in
water as well as taste masking effect is enhanced.
The advantages of effervescent tablets compared
with other oral dosage forms includes an opportunity
for formulator to improve taste, a more gentle action
on patients stomach and marketing aspects. To
manufacture these tablets, either wet fusion or heat
fusion is adopted. The tablets are compressed soft
enough to produce an effervescent reaction that is
adequately rapid. Water soluble lubricants are used
to prevent an insoluble scum formation on water
surface. To add sweetness to the formulation,
saccharin is added since sucrose is hygroscopic and
add too much of bulk to the tablet. The
manufacturing shall be done under controlled
climatic condition to avoid effervescent reaction. The
packaging is done under 25% RH at 25C. Hands of
the consumers and atmospheric moisture after
Available online on www.ijprd.com

Tablet has a better patient compliance and rapid


onset of action.
Reason for selection of Effervescent tablets of
Paracetamol
* Fast onset of action. - Effervescent tablet have major
advantage that the drug product is already in solution
at the time it is consumed.thus the absorption is faster
and more complete than with conventional tablet.faster
absorption means faster onset of action.effervescent
drug are delivered to the stomach at a pH that is just
right for absorption.many medication travel slowly
through the gastrointestinal tract or have absorption
that is hampered by food or other drug.

* No need to swallow tablet - effervescent medications


are administered in liquid form so they easy to take as

77

International Journal of Pharmaceutical Research & Development

compared to tablets or capsule.the number of people


who cannot swallow tablet or who dislike swallowing
tablet and capsule is growing.with an effervescent
dosage form, one dose can usually delivered in just 3
or 4 ounces of water.

* Good stomach and intestinal tolerance effervescent tablet dissolve fully in a buffered
solution. Reduced localized contact in the upper
gastrointestinal tract leads to less irritation and
greater tolerability.buffering also prevent gastric acids
from interacting with drug themselves, which can be a
major cause of stomach.

* More portability - effervescent tablet is more easily


transported than liquid medication because no water
is added until it is ready to use.

* Improved palatability - drugs delivered with


effervescent base, taste better than most liquids,
mixture and suspensions.superior taste masking is
achived by limiting objectionable characteristics and
complementing formulations with flavour and
fragrances.the effervescent tablet essentially include
flavouring so they they taste much better than a
mixture
of
non
effervescent
powder
in
water.morever, they produce fizzy tablets, which may
have better consumption appeal than the traditional
dosage form.

* More consistent response - drugs delivered with


effervescent technology have predictable and
reproducible pharmacokinetics profile that are much
more consistent than the tablets or capsule.

* Accurate dosing - researchers have been shown that


effervescent tablets enhance the absorption of
number of active ingredients compaired to
conventional formulations.this is because the carbon
dioxide created by the effervescent reaction can
enhance active ingredient permeability due to an
Available online on www.ijprd.com

ISSN: 0974 9446

alteration of paracellular pathway.the paracellular


pathway is the primary route of absorption of
hydrophilic active ingredients in which the solutes
diffuse into the intercellular space between epithelial
cells.it is postulated that the carbon dioxide widens the
intercellular space between cell which leads to greater
absorption of active ingredients(both hydrophilic and
hydrophobic).the increased absorption of hydrophobic
active ingredients could be due to the non polar carbon
dioxide gas molecules partition into cell membrane,thus
creating an increased hydrophobic environment,which
would allow the hydrophobic active ingredients to be
absorbed.
* Conventional tablets are often assosiate with slower
onset of action and also undergoes first pass
metabolism. Effervescent tablet avoid the first pass
metabolism and also produce rapid onset of action. Oral
liquid also provide rapid onset of action but required
carefully handling.slower onset of action and also
undergoes first pass metabolism. Effervescent tablet
avoid the first pass metabolism and also produce rapid
onset of action. Oral liquid also provide rapid onset of
action but required carefully handling.

METHODS AND MATERIALS:


Paracetamol was procured by Shri krishna
pharmaceuticals (Mumbai,India), Citric acid, Sodium
citrate (anhydrus), Fumaric acid, Sodium Benzoate was
gifted by Thomas baker (Mumbai, India), Tartaric acid,
Sodium bicarbonate (anhydrous), Sodium citrate was
gifted by Lar Chemical (Mumbai, India), Ascorbic acid,
Mannitol was gifted by Bajaj Health Care. Ltd (Mumbai,
India), Polyethylene Glycol-6000, PolyvinylpyrolidoneK-30 was gifted by Nan Hang Industrial Co-Ltd,
Simethicone was gifted by Nouvveaw Exports Pvt.Ltd,
(Mumbai, India), Acesulfame Potassium was gifted by
Shanghai fortune was Co.Ltd. China.
PREFORMULATION:
Pre-formulation is a branch of pharmaceutical
sciences that utilizes biopharmaceutical principles in the
determination of physicochemical properties of a drug

78

ISSN: 0974 9446

International Journal of Pharmaceutical Research & Development

substance. the goal of pre-formulation studies is to


choose the correct form of the substance, evaluate its
physical properties and generate a through
understanding of the materials stability under various
conditions, leading to the optimal drug delivery
system. the preformulation study focuses on the
physiochemical parameters that could effect the
development of efficacious dosage form. these
properties may ultimately provide a rationale for
formulation design. also it will help in minimizing
problems in later stages of drug development,
reducing drug development costs and decreasing
products time to market. it gives the information
needed to define the nature of the drug substance
and provide framework for the drug combination with
pharmaceutical excipients in the dosage form.
Objective:
the overall objective of preformulation testing is
to generate information useful to the formulation in
developing desired, stable and bioavailable dosage
forms.
Scope:
the use of preformulation parameters maximizes
the chances in formulating an acceptable, safe,
efficacious and stable product.
preformulation encompasses at least following tests: -

solid-state stability
excipient compatibility
consideration in effervescent tablets formulation:
there are several factors, which influence the release of
drug from effervescent tablets.




particle size
dose
solubility

Drug-excipient compatibility study:


For drug-excipient compatibility study following
excipients were studied which are used in the
experiments:
S.NO.
Excipients

Category

Citric acid

acidifying agent

Tartaric acid

acidifying agent

Fumaric acid

acidulant

Ascorbic acid

antioxidant

Sodium bicarbonate

alkalizing agent

Sodium carbonate

alkalizing agent

Polyvinylpyrollidone-30

binding agent.

Polyethylene glycol-6000

binding agent

Mannitol

binding agent

Sodium citrate

buffering agent

Sodium lauryl sulphate

lubricant

Sodium benzoate

lubricant

Acesulfum potassium

sweetener.

1.
2.
3.
4.
5.
6.
7.

i. Bulk Characterization
crystallinity, polymorphism and hygroscopicity
powder properties (flow, compaction, density,
particle size, surface area etc.)
microscopy (morphology, particle characteristics)
molecular spectroscopy (ft-ir)
ii. Solubility Analysis
solubility.
ph solubility profile
common ion effect
thermal effect on solubility
solubilization
dissolution
iii. Stability Analysis
stability (heat, light, acid, base, oxidizer)

8.
9.
10
11
12
13

According to the functional category these


excipients were mixed in the different ratio. these
mixtures were kept at 40oc + 75% RH, and 45oc

solution stability
Available online on www.ijprd.com

79

ISSN: 0974 9446

International Journal of Pharmaceutical Research & Development

At the interval of 4 weeks, the sample was


withdrawn and was subjected for analysis and related
substances. at the interval of 2 weeks and 4 weeks,
the samples were withdrawn and were tested for
following parameters:
Moisture content
Assay
Related substances
Based on results, following excipients were finally
used to fabricate robust prototype formulation of
effervescent tablets of paracetamol

Selected Excipients for Prototype Formulation:


TABLE NO-2
S.NO.
Excipients
1
Citric acid
2
3
4
5
6
7
8
9
10
11
12
13

Tartaric acid
Fumaric acid
Ascorbic acid
Sodium bicarbonate
Sodium carbonate
Polyvinylpyrollidone-30
Polyethylene glycol-6000
Mannitol
Sodium citrate
Sodium lauryl sulphate
Sodium benzoate
Acesulfum potassium
A. Evaluation of Granules of PARACETAMOL

Angle of repose
Bulk density
Tapped density
Compressibility
I) EVALUATION OF GRANULES
The ideal characteristics of a tablet that make
it a popular and acceptable dosage form are
compactness, physical stability, rapid production
capability, chemical stability and efficacy. In general
above characteristics of tablet are dictated by the
quality of the granulation from which it is made.
Many formulation and process variables involved in
Available online on www.ijprd.com

the granulation step can affect the characteristics of the


granulation produced. Therefore various methods to
measure certain granulation characteristics have been
developed to monitor granulation suitability for
tableting. The main characteristics required to be
monitored in granulation are flow properties and
compressibility.
i) Angle of repose:
It was measured by fixed funnel method. The
fixed funnel method employ a funnel that was secured
with its tip at a given height H, above graph paper that
was placed on a flat horizontal surface. Granules were
carefully poured through the funnel until the apex of
the conical pile just touches the tip of the funnel. Thus,
with R being the radius of the base of the conical pile.
Tan = H/R
Of Repose

Where, = Angle

ii) Apparent Bulk Density: (u)


an accurately weighed sample of granulation
was carefully added to the measuring cylinder with the
aid of funnel. then the volume was noted. the volume
of the packing was determined in an apparatus
consisting of a graduated cylinder mounted on a
mechanical tapping device. apparent bulk density is
determined by the following formula:U = M
VU
Where,

M = Mass Of Granulation In Gms

Vu = volume of granulation (initial


untapped volume)
iii) Packed Bulk Density: (
b)
The above procedure was followed. The final
volume was tapped till no further reduction in volume
was noted.
packed bulk density is determined by the
following formula.
b = m/vb

80

ISSN: 0974 9446

International Journal of Pharmaceutical Research & Development

Vb = volume of granulation (final


tapped volume)

in the barrel to indicate the force. The force of fracture


was recorded, and the zero force reading was deducted
from it.
Ten tablets of each formulation were
evaluated.

IV) PERCENT COMPRESSIBILITY: (%C)

III) FRIABILITY:

It is an important measure that can be


obtained from bulk density measurements. the
following formula was used to compute the percent
compressibility.

Roche friabilator
was used to determine friability of the tablets. Twenty
preweighed tablets were placed in the friabilator, which
was then operated for 100 revolutions. The tablets
were then dedusted and reweighed. The friability was
computed by following formula:

where, m = mass of granulation in gms

c = b - u x 100
b
where, b = packed bulk density

F = 100 (1

tablet shape & dimensions


hardness
thickness
friability
weight variations
disintegration time
content
uniformity
of
active
ingredients
in-vitro drug release
comparison
with
marketed
conventional tablet
I) TABLET DIMENSIONS:
Thickness and diameter were measured using
a calibrated dial caliper.
Ten tablets of each
formulation were evaluated.
II) HARDNESS:
Monsanto hardness tester was used to
evaluate hardness of tablet. The tester consists of a
barrel containing a compressible spring held between
two plungers. The lower plunger was placed in
contact with the tablet, and a zero reading was taken.
The upper plunger was then forced against a spring by
turning a threaded bold until the tablet fractures. As
the spring compressed, a pointer rides along a gauge
Available online on www.ijprd.com

u = apparent bulk density


evaluation of effervescent compressed tablets

Wo

where, f = percentage friability


wo = initial weight of 20 tablets
w = weight after friability testing
IV) WEIGHT VARIATION:
Twenty tablets were selected randomly. Tablets
were weighed individually and average weight was
calculated. Then deviation of each tablet from average
weight was calculated and percent deviation was
computed.
Preformulation study:
To ensure the compatibility of drug with
excipients the IR spectra for pure drug and prepared
granules was obtained and were compared for ensuring
no change in the principle peaks - non interference and
possible degradation.
The peaks obtained in prepared granules of
formulations were almost identical to those obtained
for pure drug reveling that there was no interaction
between drug and acids bases and other ingredients.

PROTYPE FORMULATIONS BY DIRECT COMPRESSION: FORMULA-1

81

ISSN: 0974 9446

International Journal of Pharmaceutical Research & Development

TABLE NOS.NO.

INGREDIENTS

QTY.(MG)

% W/W

paracetamol

500

34.37

citric acid (anhydrus)

231.63

15.92

ascorbic acid

200

13.75

sodium bicarbonate

277.86

19.10

sodium citrate

200

13.75

peg-6000

30

2.06

polyvinylpyrolidone-k-30

15

1.031

All Quantity in mg/tablet. COMPRESSION WEIGHT OF TABLET 1454.5 MG/TAB


FORMULA- 2
TABLE NO-4
S.NO.

INGREDIENTS

QTY.(MG)

% W/W

paracetamol

500

35.51

citric acid (anhydrus)

104.5

7.421

tartaric acid

201

14.27

sodium bicarbonate

352.5

25.03

polyvinylpyrolidone-k-30

18

1.27

sodium lauryl sulphate

18

1.27

aerosil

06

0.426

mannitol

208

1.477

All Quantity in mg/tablet. COMPRESSION WEIGHT OF TABLET - 1408 MG/TAB

Available online on www.ijprd.com

82

ISSN: 0974 9446

International Journal of Pharmaceutical Research & Development

FORMULA- 3
TABLE NO-5
S.NO.

INGREDIENTS

QTY.(MG)

% W/W

paracetamol

500

34.86

citric acid(anhydrus)

104.5

7.28

tartaric acid

201

14.01

sodium bicarbonate

352.5

24.58

sodium carbonate

18

12.55

sodium citrate

20

1.394

mannitol

208

14.50

polyvinylpyrolidone-k-30

20

1.394

acesulphum potassium

10

0.697

All Quantity in mg/tablet. COMPRESSION WEIGHT OF TABLET 1434 MG/TAB


FORMULA 4
TABLE NO-6
S.NO.

INGREDIENTS

QTY.(MG)

% W/W

paracetamol

500

11.83

citric acid (anhydrus)

520

12.30

tartaric acid

1045

24.73

sodium bicarbonate

1574

37.25

sodium carbonate

265

6.272

sodium benzoate

18

0.42

mannitol

208

4.92

polyvinylpyrolidone-k-30

60

1.42

acesulphum potassium

20

0.47

All Quantity in mg/tablet. COMPRESSION WEIGHT OF TABLET 4210 MG/TAB


FORMULA 5
Available online on www.ijprd.com

83

ISSN: 0974 9446

International Journal of Pharmaceutical Research & Development

TABLE NO-7
S.NO.

INGREDIENTS

QTY.(MG)

% W/W

paracetamol

500

12.48

citric acid (anhydrus)

485

12.11

tartaric acid

982

24.52

sodium bicarbonate

1483

37.03

sodium carbonate

250

6.24

sodium benzoate

10

0.24

mannitol

220

5.49

polyethylene glycol-

40

0.99

acesulphum potassium

20

0.48

6000

All Quantity in mg/tablet. COMPRESSION WEIGHT OF TABLET - 3989 MG/TAB


FORMULA- 6
TABLE NO-8
SR.NO.

INGREDIENTS

QTY.(MG)

% W/W

paracetamol

500

12.5

citric acid (anhydrus)

485

12.12

tartaric acid

982

24.55

sodium bicarbonate

1483

37.07

sodium carbonate

250

6.25

sodium benzoate

15

0.37

mannitol

225

5.62

polyvinyl pyrolidone-k-30

60

1.5

All Quantity in mg/tablet. COMPRESSION WEIGHT OF TABLET - 4000 MG/TAB


FORMULA-7
TABLE NO-9
Available online on www.ijprd.com

84

ISSN: 0974 9446

International Journal of Pharmaceutical Research & Development

S.NO.

INGREDIENTS

QTY.(MG)

% W/W

paracetamol

500

12.72

citric acid (anhydrus)

490

12.46

tartaric acid

982

24.98

sodium bicarbonate

1483

37.73

sodium carbonate

250

6.36

sodium benzoate

20

0.50

polyvinylpyrolidone-k-30

115

2.92

acesulphum potassium

30

0.76

All Quantity in mg/tablet.


COMPRESSION WEIGHT OF TABLET 3870 MG/TAB
FORMULA - 8
NO-10
S.NO.

TABLE

INGREDIENTS

QTY.(MG)

% W/W

paracetamol

500

13.36

citric acid (anhydrus)

480

12.83

tartaric acid

970

25.93

sodium bicarbonate

1400

37.44

sodium carbonate

240

6.41

sodium benzoate

25

0.66

polyvinylpyrolidone-k-30

80

2.31

acesulphum potassium

20

0.53

All Quantity in mg/tablet.


COMPRESSION WEIGHT OF TABLET - 3715 MG/TAB
FORMULA-9
TABLE NO-11

Available online on www.ijprd.com

85

ISSN: 0974 9446

International Journal of Pharmaceutical Research & Development

S.NO.

INGREDIENTS

QTY.(MG)

% W/W

paracetamol

500

13.53

citric acid (anhydrus)

480

12.99

tartaric acid

960

25.98

sodium bicarbonate

1350

36.53

sodium carbonate

210

5.68

sodium benzoate

30

0.81

polyvinylpyrolidone-k-30

100

2.70

acesulphum potassium

15

0.40

All Quantity in mg/tablet


COMPRESSION WEIGHT OF TABLET -3695 MG/TAB

2) Base granulation

Wet Granulation: -

(i) In base granulation firstly the sodium bicarbonate,


sodium carbonate were blended and passed through
sieve no.# 40.

The Wet granulation process performed into three


steps.
Dry Mixing & Granulation
Lubrication of Granules

(ii) In the second step the binding agent PVP-K-30 was


dissolved in organic solvent i.e. methylene chloride.

There are two steps in dry mixing & granulation


process i.e. Acid granulation & base granulation.

The above organic solvent was mixed


with base portions i.e. sodium bicarbonate & sodium
carbonate. The obtained wet mass passed through sieve
no.# 20 & kept in tray dried at 600c for 1 hr.until the
L.O.D.was observed about below 1%. (On IR at 1050C for
5 minutes).

1) Acid granulation

Lubrication of acid and base granules: -

Compression of Lubricated Granules


Dry Mixing & Granulation: -

(i) In first step Weight the Citric acid, Tartaric acid


were blended and passed through Sieve No.# 40.
(ii) In second step simethicone was dissolved in
organic solvent i.e.methylene chloride.
The above organic solvent was mixed with
acid portions i.e. citric acid & tartaric acid. The
obtained wet mass passed through sieve no.# 20 &
kept in tray dried at 600c for 1 hr.until the L.O.D.was
observed about below 1%. (On IR at 1050C for 5
minutes).
Available online on www.ijprd.com

after drying at R.T.of both granules i.e. acid granules


and base granules were mixed. After mixing of both
granules the Paracetamol, Acesulphum potassium and
lubricating agent sodium benzoate add to the granules
and well mixed.
Compression of Lubricated Granules:The Lubricated granules were
compressed into tablet by using Single rotary tablet

86

ISSN: 0974 9446

International Journal of Pharmaceutical Research & Development

Punching machine, 12 stations, with 24.8mm punch


sets.

FORMULA-1
TABLE NO-12

PROTYPE FORMULATIONS BY WET GRANULATION: TABLE NO-12


S.NO.

INGREDIENTS

QTY.(MG)

% W/W

paracetamol

500

34.37

citric acid (anhydrus)

231.63

15.92

ascorbic acid

200

13.75

sodium bicarbonate

277.86

19.10

sodium citrate

200

13.75

peg-6000

30

2.06

polyvinylpyrolidone-k-30

15

1.031

All Quantity in mg/tablet


COMPRESSION WEIGHT OF TABLET 1454.5 MG/TAB
FORMULA-2
TABLE NO-13
S.NO.

INGREDIENTS

QTY.(MG)

% W/W

paracetamol

500

35.51

citric acid (anhydrus)

104.5

7.421

tartaric acid

201

14.27

sodium bicarbonate

352.5

25.03

polyvinylpyrolidone-k-30

18

1.27

sodium lauryl sulphate

18

1.27

aerosil

06

0.426

mannitol

208

1.477

Available online on www.ijprd.com

87

ISSN: 0974 9446

International Journal of Pharmaceutical Research & Development

All Quantity in mg/tablet. COMPRESSION WEIGHT OF TABLET - 1408 MG/TAB


FORMULA-3
TABLE NO-14
S.NO.

INGREDIENTS

QTY.(MG)

% W/W

paracetamol

500

34.86

citric acid (anhydrus)

104.5

7.28

tartaric acid

201

14.01

sodium bicarbonate

352.5

24.58

sodium carbonate

18

12.55

sodium citrate

20

1.394

mannitol

208

14.50

polyvinylpyrolidone-k-30

20

1.394

acesulphum potassium

10

0.697

All Quantity in mg/tablet


COMPRESSION WEIGHT OF TABLET 1434 MG/TAB
FORMULA-4
TABLE NO-15
S.NO.

INGREDIENTS

QTY.(MG)

% W/W

paracetamol

500

11.83

citric acid (anhydrus)

520

12.30

tartaric acid

1045

24.73

sodium bicarbonate

1574

37.25

sodium carbonate

265

6.272

sodium benzoate

18

0.42

mannitol

208

4.92

polyvinylpyrolidone-k-30

60

1.42

Available online on www.ijprd.com

88

ISSN: 0974 9446

International Journal of Pharmaceutical Research & Development

simethicone

15

0.35

10

acesulphum potassium

20

0.47

All Quantity in mg/tablet. COMPRESSION WEIGHT OF TABLET 4225 MG/TAB


FORMULA-5

TABLE NO-16

S.NO.

INGREDIENTS

QTY.(MG)

% W/W

paracetamol

500

12.48

citric acid (anhydrus)

485

12.11

tartaric acid

982

24.52

sodium bicarbonate

1483

37.03

sodium carbonate

250

6.24

sodium benzoate

10

0.24

mannitol

220

5.49

simethicone

15

0.37

polyethylene glycol-

40

0.99

10

acesulphum potassium

20

0.48

6000

All Quantity in mg/tablet. COMPRESSION WEIGHT OF TABLET - 4004 MG/TAB


FORMULA- 6
TABLE NO-17
s.no.

Ingredients

QTY.(MG)

% W/W

paracetamol

500

12.5

citric acid (anhydrus)

485

12.12

tartaric acid

982

24.55

sodium bicarbonate

1483

37.07

sodium carbonate

250

6.25

sodium benzoate

15

0.37

Available online on www.ijprd.com

89

ISSN: 0974 9446

International Journal of Pharmaceutical Research & Development

mannitol

225

5.62

polyvinylpyrolidone-k-30

60

1.5

All Quantity in mg/tablet. COMPRESSION WEIGHT OF TABLET - 4000 MG/TAB


FORMULA-7
S.NO.

TABLE-18

INGREDIENTS

QTY.(MG)

% W/W

paracetamol

500

12.72

citric acid (anhydrus)

490

12.46

tartaric acid

982

24.98

sodium bicarbonate

1483

37.73

sodium carbonate

250

6.36

sodium benzoate

20

0.50

polyvinylpyrolidone-k-30

115

2.92

simethicone

60

1.52

acesulphum potassium

30

0.76

All Quantity in mg/tablet. COMPRESSION WEIGHT OF TABLET 3930 MG/TAB


FORMULA 8
TABLE NO-19
S.NO.

INGREDIENTS

QTY.(MG)

% W/W

paracetamol

500

13.36

citric acid (anhydrus)

480

12.83

tartaric acid

970

25.93

sodium bicarbonate

1400

37.44

sodium carbonate

240

6.41

sodium benzoate

25

0.66

polyvinylpyrolidone-k-30

80

2.31

Available online on www.ijprd.com

90

ISSN: 0974 9446

International Journal of Pharmaceutical Research & Development

simethicone

25

0.66

acesulphum potassium

20

0.53

All Quantity in mg/tablet. COMPRESSION WEIGHT OF TABLET - 3740 MG/TAB


FORMULA - 9
TABLE NO-20
S.NO.

INGREDIENTS

QTY.(MG)

% W/W

paracetamol

500

13.53

citric acid (anhydrus)

480

12.99

tartaric acid

960

25.98

sodium bicarbonate

1350

36.53

sodium carbonate

210

5.68

sodium benzoate

30

0.81

polyvinylpyrolidone-k-30

100

2.70

simethicone

50

1.35

acesulphum potassium

15

0.40

All Quantity in mg/tablet. COMPRESSION WEIGHT OF TABLET -3695 MG/TAB


TABLE NO 21
FORMUL OBSERVATION
A
DIRECT COMPRESSION

WET GRANULATION

F1

Capping problem,less effervescence

capping problem,less effervescence

F2

Capping problem,less effervescence

Capping problem,less effervescence

F3

Capping problem,less effervescence

Capping problem,less effervescence

F4

Tablets
having
very
quick Tablets
having
very
quick
effervescence but the tablet surface effervescence,the
tablet
surface
found rough.
become smooth compaired to direct
compression.

Available online on www.ijprd.com

91

International Journal of Pharmaceutical Research & Development

F5

Tablet gives good effervescence but


the some particles settle at the bottom
of the solution,capping problem also
occur.

Tablet
gives
good
effervescence,solution
become
somewhat clear,not so much capping
problem.

F6

Tablet gives good effervescence but


the capping problem also as such.
The tablet gives good effervescence,
capping problem but the some
particles become settled down, the
hardness also not good.

Tablet gives good effervescence but


the capping also as such.
The tablet gives good effervescence ,
no capping problem and the solution
become found to be clear,hardness of
tablet also good compaired to other
batches.
The tablet gives good effervescence ,
no capping problem and the solution
become found to be clear,hardness of
tablet not good.
Tablet gives slow effervescent.the
other properties like hardness,
appearance are satisfactory.

F7

F8

The tablet found to be good hardness


but the capping problem somewhat
occur, solution found to be not clear.

F9

Tablet gives slow effervescent.the


other properties like hardness,
appearance are not so good.

 In direct compression the simethicone was not


used. But in wet granulation method it was
used.
 From the above study it was concluded that
the wet granulation provide good tablet
characteristics and was selected as final
formulation
of
Effervescent
tablets
preparation.
RESULTS AND DISCUSSION:
Prior to the formulation, preformulation study
was carried out on drug and excipents. in the present
work, formulation part divided into four steps. in first
step, placebo tablets were made using different acids
and bases in different concentrations. the detailed
composition is shown in table. the granules were
subjected to evaluation such as angle of repose, bulk
density, tapped density. the placebo tablets were
evaluated for various physical parameters such as
thickness, hardness, friability, weight variation,
disintegration, and solubility. from these best acid
base combination and various other ingredients that
are usually water-soluble were selected.

Available online on www.ijprd.com

ISSN: 0974 9446

in second step the tablets were prepared by


using selected different acid base concentrations were
prepared. the detailed composition is shown in table
no. the granules were subjected to evaluation such as
angle of repose, bulk density, tapped density. the
tablets were evaluated for various physical parameters
such as thickness, hardness, friability, weight variation
and disintegration. the observations were confirmed to
be comparable to those observed in pre-formulation
trials. from this study the following proportions of the
key excipients were finalized:
citric acid 12.5%, tartaric acid 25.17%, sodium
bicarbonate 38.02%, and sodium carbonate 6.41%.
in third step, the tablets were prepared by
different methods, viz. direct compression and wet
granulation.
Wet granulation
Preparation Of Acid Granule
In the preparation of acid granules: the acids
were blended with simethecone i.e. citric acid and
tartaric acid. for this simethicone oil dissolved in solvent
methylene chloride and then used to coat the sifted
blend of the acids. the wet mass the mass was passed
through the sieve no.20 # and the wet granules so

92

ISSN: 0974 9446

International Journal of Pharmaceutical Research & Development

Available online on www.ijprd.com

concentration
mcg/ml

absorbance

0.022

0.044

0.064

0.087

0.115

0.135

0.157

0.180

0.206

10
slope=0.0229

0.240
r2=0.996

Fig.No.1-Standard Curve Of Paracetamol


Standard curve of Paracetamol
y = 0.0229x

0.3

R2 = 0.9968

0.25
A b s o rb a n c e

obtained were dried in a tray drier for about 60 min at


53c+ 2c to get lod less than 1.0% on ir. the dried
granules were passed through mesh no. 16 prior to
lubrication.
Preparation Of Base Granules
In the preparation of base granules: the bases
i.e. sodium bicarbonate and sodium carbonate
granulated with the pvp-k-30. the pvp-k-30 was
dissolved in a solvent methylene chloride to form
clear solution. the obtained wet mass was passed
through sieve no.20 # and was dried at 53c+ 2c for
about 1 hour to get lod less than 1.0% on ir. the dried
granules were passed through mesh no. 16 prior to
lubrication.
The Lubrication Of Granules:
The
lubricants
were passed through mesh 40 and were mixed with
the blend of sized base granules and sized acid
granules. the lubricating agents in the effervescent
tablet were water-soluble.
from this study it was concluded that the wet
granulation process was better than direct
compression
the granules were subjected to evaluation
such as angle of repose, bulk density, tapped density.
the tablets were evaluated for various physical
parameters such as thickness, hardness, friability,
weight variation, disintegration, content of active
ingredient and in-vitro dissolution study. the
promising formulations (formula no. f7) were
compared with marketed products for drug content,
disintegration, carbon dioxide and in-vitro drug
release profile.
TABLE N-22 STANDARD CALIBRATION CURVE FOR
PARACETAMOL(PH-1.2)
accurately weighed 100 mg of paracetamol was
dissolved in 100.0 ml of 0.1n hcl. 10.0 ml of this stock
solution was further diluted to 100.0 ml with 0.1n
hcl.from this dilution 10.0 ml was further diluted upto
100.0 ml with 0.1 n hcl.the aliquots of 1.0 ml., 2.0 ml,
3.0 ml, 4.0 ml, 5.0 ml, 6.0 ml, 7.0 ml, 8.0 ml, 9.0 ml
and 10 ml were pipetted out and were made upto 10
ml volume with 0.1 n hcl individually. the absorbance
of all these solutions were measured at 249 nm using
u.v.spectrometer.

0.2
0.15
0.1
0.05
0
0

10

12

concentration(mcg/ml)

EVALUATION OF TABLETS:
I) TABLET DIMENSIONS:
tablet dimension include thickness and diameter
of tablet. five tablet of each formulation were evaluated
and mean thickness values obtained are shown in table
no.-.
the value indicates that, die fill was uniform and
compression force was consistent.
II) FRIABILITY:

93

International Journal of Pharmaceutical Research & Development

friability values for each formulation are


recorded in table no.-. the values of the preferred
formulas are within acceptable limit, implying good
compactness and strength of these formulation.
III) AVERAGE WEIGHT AND WEIGHT VARIATION:
twenty tablets of each formulation were evaluated.
the mean values and weight variation of each
formulation are recorded in table no. the values
obtained indicate that all the tablets of different
formulations meet the ip/ u.s.p. requirements.
the observed narrow range weight variation indicates
granule flow ability; desired packing characteristics

ISSN: 0974 9446

and uniform dies fill of all the formulations. this is


supported by the acceptable flow properties of granules
obtained in the pre-formulation.
IV) DISINTEGRATION TIME:
the disintegration time test was carried out for each for
each formulation. table no.- shows the results of the
disintegration time of each formulation .the acids and
bases are used in 38% and 45% respectively in final
formulation.

FIG.NO.2- IDENTIFICATION OF PARACETAMOL BY H.P.L.C.

Available online on www.ijprd.com

94

International Journal of Pharmaceutical Research & Development

ISSN: 0974 9446

FIG.NO.3-IMPURITY PROFILE OF PARACETAMOL

FIG.NO.4- IR CURVE OF API (PARACETAMOL)

Available online on www.ijprd.com

95

International Journal of Pharmaceutical Research & Development

ISSN: 0974 9446

FIG.NO.5- IR CURVE OF API (PARACETAMOL) + CITRIC ACID + TARTARIC ACID

FIG.NO.7- IR CURVE OF API (PARACETAMOL) + SODIUM BICARBONATE + SODIUM CARBONATE

Available online on www.ijprd.com

96

ISSN: 0974 9446

International Journal of Pharmaceutical Research & Development

STABILITY STUDIES:
ACCELERATED STABILITY TESTING:
since the period of accelerated stability testing
can be as long as 3 months for the effervescent tablet.
therefore it is essential to devise a method that will
help rapid prediction of long-term stability of drug.
the accelerated stability testing is defined as
the validated method by which the product stability
may be predicted by storage of the product under
conditions that accelerate the change in defined and
predictable manner.

the stability studies of formulated tablets were


carried out at 40 oc, rh 75% and at room temperature
for one month. the effects of temperature and time on
the physical characteristics of the tablet were evaluated
for assessing the stability of the prepared
formulations.the stability studies were carried out when
the room temperature was 20 to 25 oc. the different
parameters that were studied are in vitro disintegration
time.
THE RESULTS WERE SUMMARIZED IN TABLES

TABLE NO:23- STABILITY PARAMETERS OF FORMULATION F7STORED AT ROOM TEMPERATURE


INITIAL
AFTER 15 DAYS
AFTER 30 DAYS
PARAMETER
Drug Content (%)

98%

Available online on www.ijprd.com

97.7%

96%

97

ISSN: 0974 9446

International Journal of Pharmaceutical Research & Development

TABLE NO.24.- STABILITY STUDY OF IN-VITRO DISSOLUTION FOR FORMULATION F7 AT R.T.


% DRUG RELEASE
TIME (MIN)

0
1
2
3
5

INITIAL

AFTER 15 DAYS

AFTER ONE MONTHS

100.15

100.1

99.91

99.29

95.76

95.84

94.22

94.53

104.5
102.45

99.24
99.15

TABLE NO.25- STABILITY PARAMETERS OF FORMULATION F7 STORED AT TEMPERATURE 40OC AND RH 75%.
AFTER
ONE
INITIAL
AFTER 15 DAYS
PARAMETER
MONTHS
Drug content (%)
98%
97.7%
96%
In-vitro disint. Time
65
70
(sec)
76

TABLE NO.26- STABILITY STUDY OF IN-VITRO DISSOLUTION FOR FORMULATION F7 STORED AT TEMPERATURE 40OC
AND RH 75%
PARAMETER

INITIAL

AFTER 15 DAYS

AFTER
MONTHS

Drug content (%)

104.5%

97%

98%

In-vitro disint. Time


65
(sec)

Available online on www.ijprd.com

70

ONE

76

98

ISSN: 0974 9446

International Journal of Pharmaceutical Research & Development

TABLE NO.27- PROPERTIES OF THE PREPARED FORMULATIONS


FD1

FD2

FD3

FD4

FD5

FD6

FD7

FD8

FD9

THICKNESS (MM)

5.60

5.39

5.49

5.95

5.90

5.85

5.85

5.88

5.83

DISINTEGRATION
TIME, SECONDS
% COMPRESSIBILITY

90

100

65

69

75

70

62

66

72

PROPERTY

14.96 31.57 26.76 18.30 20.48 27.67 12.50 13.13 13.13


TABLE NO.28: EFFECT OF ACIDS AND BASES ON EFFERVESCENT TIME OF TABLETS
FD1

FD2

FD3

FD4

FD5

FD6

FD7

FD8

FD9

PROPERTY
Bulk Density,
G/CM3
0.50

0.52

0.52

0.58

0.66

0.66

0.625

0.58

0.58

0.588

0.76

0.71

0.71

0.83

0.90

0.7142

0.66

0.66

14.96

31.57

26.76

18.30

20.48

27.67

12.50

13.13

13.13

Thickness (MM)

5.60

5.39

5.49

5.95

5.90

5.85

5.85

5.88

5.83

disintegration
TIME (SEC.)

90

100

65

55

59

70

62

66

72

water content
( l.o.d.) %

1.8

1.8

1.8

1.6

3.4

1.4

1.0

1.2

1.4

24.8

24.8

24.8

24.8

24.8

24.8

24.8

24.8

24.8

tapped density
G/CM3
%
Compressibility

DIAMETER (MM)

Available online on www.ijprd.com

99

ISSN: 0974 9446

International Journal of Pharmaceutical Research & Development

TABLE NO.29- COMPOSITION OF EFFERVESCENT TABLETS OF PARACETAMOL (WET GRANULATION)


Ingredients

F1

F2

F3

F4

F5

F6

F7

F8

F9

paracetamol

500

500

500

500

500

500

500

500

500

citric acid (anhydrus)

231.63

104.5

525

520

485

485

490

480

480

tartaric acid

201

1045

1045

982

982

982

970

960

ascorbic acid

fumaric acid

191.96

sodium bicarbonate

277.86

352.5

1577

1574

1483

1483

1483

1400

1350

sodium carbonate

265

265

250

250

250

240

210

sodium citrate

200

20

sodium benzoate

18

10

15

20

25

30

208

208

208

220

225

40

60

115

80

100

mannitol
peg-6000

30

20

pvp-k-30

15

18

20

60

simethicone

15

15

60

25

50

acesulphum potassium

10

20

20

30

20

15

TABLE NO.30- COMPOSITION OF EFFERVESCENT TABLETS OF PARACETAMOL (DIRECT COMPRESSION)


Ingredients

F1

F2

F3

F4

F5

F6

F7

F8

F9

paracetamol

500

500

500

500

500

500

500

500

500

citric acid (anhydrous)

231.63

104.5

525

520

485

485

490

480

480

tartaric acid

201

1045

1045

982

982

982

970

960

ascorbic acid

fumaric acid

191.96

Available online on www.ijprd.com

100

ISSN: 0974 9446

International Journal of Pharmaceutical Research & Development

sodium bicarbonate

277.86

352.5

1577

1574

1483

1483

1483

1400

1350

sodium carbonate

265

265

250

250

250

240

210

sodium citrate

200

20

sodium benzoate

18

10

15

20

25

30

208

208

208

220

225

40

60

115

80

100

30

20

15

mannitol
peg-6000

30

20

pvp-k-30

15

18

20

60

acesulphum potassium

10

20

20

TABLE NO.31-COMPARISON OF F7 FORMULATION WITH LEADING MARKETED SAMPLES I.E.ENO FRUIT SALT, HISTAC
TABLETS
FD7

MARKTED EFFERVESCENT SALT

MARKTED EFFERVESCENT TABLET

Bulk density (g/cm3)

0.625

0.7142

0.5882

Tapped density (g/cm3)

0.7142

0.7692

0.666

% Compressibility

12.50

7.15

11.62

Hardness (kg/cm2)

3.9

4.7

Thickness (mm)

5.85

5.62

62
1.0

30
0.7

55
0.8

24.8

24.8

0.63g/tab(16.34%)

19%

16.23%

PROPERTY

Disintegration
time (sec.)
Water content
(l.o.d.) %
Diameter (mm)
Co2 content

SUMMARY AND CONCLUSION:


The study was undertaken with an aim
to formulate effervescent tablet of analgesic
and antipyretic drug (paracetamol). The
Available online on www.ijprd.com

literature review showed that paracetamol having


simmilar mechanism of action to aspirin because
simmilarity in structure.paracetamol act by reducing
production of prostaglandin which involved in pain
101

International Journal of Pharmaceutical Research & Development

and fever process, by inhibiting the cyclo-oxygenase


enzyme.
In present work an attempt has been
made to formulate an effervescent tablet
containing immediate release of paracetamol using
various acids and bases. In present work we are
used different acids and bases in different
concentration
1)
In the preformulation study,
compatibility evaluation was performed
which implies that drug; acids, bases and
other excipient are compatible with each
other.
2)

The formulation of tablets was done


by using wet granulation as well as dry
granulation.in
that
technique
wet
granulation which was found acceptable.

All the formulations were subjected to


various evaluation studies. Result of the
evaluation of granules and evaluation of tablet
dimensions, hardness, friability, weight variations.

In the effervescent tablet the water content can


be measured by Karl Fischer titration method. We
are also subjected to carbon dioxide content in
the effervescent tablets.
Uniformity in tablet dimensions implies that die
fill was uniform and compression force was
constant.
Hardness values reveal that tablets are having good
mechanical strength and handling characteristics.
Friability values dictate good compactness of the
formulations.
The weight variation of all formulated tablets
was satisfactory,
attributed
by
the
acceptable flow properties of granules.
Content uniformity of active ingredient of
all the formulations are within acceptable
limit and ensures dosage uniformity.
The promising formulation F7 obtained in
evaluation studies.

Available online on www.ijprd.com

ISSN: 0974 9446

The placebo tablets were prepared by


using different acids and bases and its
combination in different concentrations. The total
nine placebo tablets were prepared and evaluated
for hardness, disintegration time, weight
variation and solubility. All the formulation
shows hardness and weight variation with in limit
but the combination of citric acid (12.56 %),
tartaric
acid
(25.17%),
sodium
bicarbonate(38.20%),sodium carbonate (6.41%)
for the final formulation, and the binding agent
PVP-K-30 (2.94%) and sodium benzoate
(0.52%).because these ingredients shows the
good effervescent reaction and has no problem in
capping and sticking like other formulation.
The effervescent tablet can be prepared
using different acids such as citric acid, tartaric
acid, fumaric acid, and ascorbic acid in different
concentration. In that also we are used the various
lubricants and binding agents. There are 7
formulations that contain the citric acid, tartaric
acid, sodium bicarbonate, and sodium carbonate.
These 7 formulations evaluated for hardness,
friability, and weight variation, effervescent
time etc.all the formulation. All the formulation
found effervescent upto 72 sec. But the formula
having
citric
acid(12.56%),tartaric
acid
(25.17%),sodium bicarbonate(38.20%)and sodium
carbonate(2.94%).so these concentration of
acids and bases used for the final formulation.
The effervescent tablet were prepared by
different preparation method such as Direct
compression, wet granulation. The prepared
tablets were evaluated for content uniformity and
physical parameters. The direct compression was
found there was an capping problem. so the upper
surface of tablets not properly set. but with the help of
wet granulation technique the powder become free
flowing and the compression of the tablets so good
as compaired to the direct compression reason
behind the choosing the wet granulation because
in dry granulation technique the capping and
sticking problem occur.but by wet granulation

102

International Journal of Pharmaceutical Research & Development

technique the granules become good flowing


properties as
compaired to direct compression. because
wet granulation provides the acids and bases
from the environmental moisture. and capping
problem was reduced. At the time of
manufacturing of effervescent tablet the
strictly humidity and temperature should be
maintained. the L.O.D.of the tablet should be
less than 1%. Because if one-water molecules
present in the effervescent tablet then the
obtained effervescent reaction of the tablet
should be very less.
The stability study i.e. accelerated stability
study according to I.C.H.guidelines can be
performed i.e 400 C ,75% RH. The stability can
also be performed at R.T, 45C, cold temperature
i.e. 2-5C. formulation showed no significant
variations for the above mentioned parameters
and it was stable for the specified time period.
From the above summary it was
concluded that, the effervescent tablets of
parac etamol can b e formul ated for quick
analgesic
an d
antipyretic
ac tion
by
effervescence reaction using citric acid
(12.56%), tartaric acid (25.17%), sodium
bicarbonate (38.20%) and sodium carbonate
(2.94%).gives the better effervescence. the PVP-K-30
used as the binding agent. sodium benzoate (0.5%) as
lubricating agent.
ACKNOWLEDGEMENT
Authors are thankful to Prof.(Dr.) V.Rama
Mohan Gupta, principal Pulla Reddy Institute of
Pharmacy Dundigal,Andhra Pradesh and providing all
the facilities for this research Project.
REFERENCES
1. Leon Lachman, Herbert a liberman, joseph L.
Kanig in theory and practice of industrial
pharmacy 2nd edition. 1985 varghese
publication 341.
Available online on www.ijprd.com

ISSN: 0974 9446


2. mohrle R Effervescent tablets in Liberman,
Lachman L. Schwartz. Pharmaceutical dosage
form, Tablets vol-I first Indian reprint (2005)
Marcel dekkar inc New york -285-292.
3. Raymond mohrle, Liberman abd Lachman
Effervescent
Tablet
SPI
pharma
Pharmaceutical dosage form Tablets, Vol-I
4. Howard C.Ansel, Lloyd, Allen Jr, Nocholas and
Popovich in Effervescent granules8th edition
pharmaceutical dosage from and drug
delievery international student edition.-200
172-178.
5. U.S. Patent No-6440926 (Roberto Morelli,
sylvestre cabceil)
6. O connor, R.E.ipple E.G. Schwartz, Powder as
dosage form Remingtion 19th edition 16111614
7. Brentford G.B. Effervescence in chewable base
U.S. Patent No-5962022 (1999) Smithkline
Beecham
8. Astra
Medica
A.G.(DE)
Solid
rapidly
disintegrating formulation U.S. Patent No6245353 (2001)
9. Brentford G.B. Effervescent formulation of
Amoxicillin U.S. Patent No-6077536 (2000)Beecham Group PLC
10. Losan Pharma Gmph effervescent ibuprofen
prepration U.S. Patent No-6171617 (2001)(Neuenberg. DE)
11. Cima Labs Inc sublingual and buccal effervescent
prepration U.S. Patent No-6200604 (2001)
(Minneapolis, MN)
12. Chiesi Farmaceutici SPA movel method for
producing effervescent tablet U.S. Patent No6284272 (2001)
13. Therapeutic effervescent compisition U.S.
Patent No-4687662
14. S.I.Saleh in An approach to the direct
compressible
effervescent
tablets
Lab
Pharmacotech, Fac, Pharma f-67048, strasboug
celex 1983
15. Swierkosz T.A. Jordan L. Mcgough.K.(2002)
Action of paracetamol on COX in tissue and cell.

103

International Journal of Pharmaceutical Research & Development

16. L.Kalantzi,
C.Reppas,
J.B.
Dressman,
G.L.Amidon, H.E.Junginger in Journal of
Pharmaceutical Science 95,4-14.
17. Wikipedia of paracetamol.
18. Bernard Bannworth, Fabienne, in Drugs
2003, 2, 5-13.
19. Raymond C. Rowe, paul J. Sherskey,sain C.
owen.in Handbook of Pharmaceutical
excipients Ascorbic acid (2000), 48-50
20. Raymond C. Rowe, paul J. Sherskey,sain C.
owen.in Handbook of Pharmaceutical
excipients Fumaric acid (2000), 293-294.
21. Raymond C. Rowe, paul J. Sherskey,sain C.
owen.in Handbook of Pharmaceutical
excipients Citric acid (2000), 187.
22. Raymond C. Rowe, paul J. Sherskey,sain C.
owen.in Handbook of Pharmaceutical
excipients Tartaric acid (2000), 770-771.
23. Raymond C. Rowe, paul J. Sherskey,sain C.
owen.in Handbook of Pharmaceutical
excipients Sodium bicarbonate (2000), 665667.
24. Raymond C. Rowe, paul J. Sherskey,sain C.
owen.in Handbook of Pharmaceutical
excipients Sodium carbonate (2000), 668.
25. Raymond C. Rowe, paul J. Sherskey,sain C.
owen.in Handbook of Pharmaceutical
excipients Acesulfum potassium (2000), 4-5.
26. Raymond C. Rowe, paul J. Sherskey,sain C.
owen.in Handbook of Pharmaceutical
excipients Sodium banzoate (2000), 662-663.
27. Parikh P.M,Taylor and Francis Handbook of
Pharmaceutical granulation Technology 2nd
edition 154 New York 365-383.
28. Robert E Lece Amerilab Technology.
29. Eichman J.D and Robinson, J.R. Mechenistic in
Studies on Effervescent induced permeability

ISSN: 0974 9446


enhancement,
Pharmaceutical
Research1998,15(6),925-930.
30. Colletta, V.Kennon, in the preparation
Technology for effervescent product journal of
Pharmaceutical Sciences-1964, 53: 1524-1525.
31. Goreth A. Lewis Didier, Mathieu, in
Pharmaceutical experimental Design 92: 9497.
32. Banker G.S Anderson N.R. in Theory and
practice of industrial Pharmacy Edited by
Lachmen 3rd edition, Varghese publishing house
(Mumbai)-1991, 296-317.
33. Colas, Chacartegur, Temprano, Gonzalez R,
Munaz, Cacho P in Abuse pattern of analgesic
in chronic daily headache: A study in general
popuylation 2005, 205(12), 583-587.
34. Richerdson J.H Marnett L.J.Arnolf D.M in
Determination of Cellular Specificity of
Acetaminophen as inhibitor of prostaglanding
H2 Synthesis proce, Natio Academic Science USA
99.
35. Forrest
J.A.
Clements
J.A.
Clinical
Pharmacokinatic of paracetamol in Clinical
pharmacokinatics-7 (1982),93-107.
36. Clarks isolation and identification of drugs
2edition Pharmaceutical press, London 1986,
838.
37. David james, Chris Petty, Thermonicolet
spectroscopy reservation centre USA (Article file
no. 24231.pdf)
38. A.Rostomi, Hodjegan, M.R. shiran, T.J.Grattan in,
Drug Development and Industrial pharmacy
june 2002 vol-28, 5: 533-543.
39. Pubchem.ncbi.nlm.gov.summary.

*****

Available online on www.ijprd.com

104

You might also like